Two of the genes identified from the previously published DNA sequence of the Us component of the varicella-zoster virus (VZV) genome were predicted to encode membrane proteins with polypeptide molecular weights of 39 000 (39K) and 70K. A rabbit antiserum directed against a unique peptide containing the seven amino acid residues at the carboxy terminus of the 39K gene product specifically precipitated glycoproteins with apparent molecular weights of 55K and 45K from VZV-infected cells labelled with [3H]mannose. The complete inhibition of precipitation of gp55 by free peptide and the partial inhibition of precipitation of gp45 support the conclusion that the 39K gene encodes gp55 and perhaps gp45. The number of VZV genes currently thought to encode glycoproteins is discussed in view of this finding.
Identification of the Products of a Varicella-Zoster Virus Glycoprotein Gene

SUMMARY
Two of the genes identified from the previously published DNA sequence of the Us component of the varicella-zoster virus (VZV) genome were predicted to encode membrane proteins with polypeptide molecular weights of 39 000 (39K) and 70K. A rabbit antiserum directed against a unique peptide containing the seven amino acid residues at the carboxy terminus of the 39K gene product specifically precipitated glycoproteins with apparent molecular weights of 55K and 45K from VZV-infected cells labelled with [3H]mannose. The complete inhibition of precipitation of gp55 by free peptide and the partial inhibition of precipitation of gp45 support the conclusion that the 39K gene encodes gp55 and perhaps gp45. The number of VZV genes currently thought to encode glycoproteins is discussed in view of this finding.
Varicella-zoster virus (VZV) is a herpesvirus, causing chickenpox in man on primary infection and shingles after reactivation of latent virus. This complex virus expresses several glycoproteins in infected cells (Asano & Takahashi, 1979; Grose, 1980; Shemer et al., 1980; Zweerink & Neff, 1981; Grose & Friedrichs, 1982; Shiraki et al., 1982) , but it appears from the studies discussed below using monoclonal antibodies that more than one species of glycoprotein may be encoded by each glycoprotein gene. Clearly, it is important to identify all the VZV glycoprotein genes in order to study the interrelationships and functions of the encoded species, and to design potential vaccines based on these immunologicalty important constituents of VZV.
The DNA sequence of VZV defines every protein expressed by the virus genome. The functions of most proteins cannot yet be predicted from primary amino acid sequences derived from DNA sequence data, but the primary translation products of genes coding for membraneassociated glycoproteins are exceptional because they usually exhibit characteristic features. These include a hydrophobic region close to the amino terminus, which is necessary for insertion of the nascent protein into the membrane of the endoplasmic reticulum, and a highly hydrophobic region near the carboxy terminus, which spans the membrane, followed by several basic residues thought to be responsible for anchoring the mature glycoprotein in the membrane. From an analysis of the DNA sequence of the Us component of the VZV genome, Davison (1983) identified two adjacent genes encoding 39K and 70K primary translation products with these features. Ellis et al. (1985) showed subsequently that the 70K gene encodes at least one of a family of glycoproteins which they had defined previously as gC by means of monoclonal antibodies (Keller et al., 1984) . The approach that these workers used was to insert random VZV DNA fragments into an Escherichia coli expression plasmid and screen recombinant clones with a monoclonal antibody against gC. One clone recognized by the antibody contained a VZV DNA insert which was mapped to the 70K gene by molecular hybridization and DNA 0000-6652 © 1985 SGM sequencing. This approach is limited in that it can be used to map only those genes encoding proteins against which a specific antibody is available, and the antibody must be able to react with the form of the antigen expressed in E. coB. In the present study an approach with wider application, which has proved successful in other systems, was used in order to identify the product of the 39K gene. The gene product was immune-precipitated using an antiserum against a peptide predicted from the DNA sequence.
A rabbit was immunized with a conjugate between bovine serum albumin (BSA) and the peptide NH2 Tyr-Val-Val-Asn-Pro-Phe-Val-Lys-COOH (synthesized to order by Cambridge Research Laboratories, Cambridge, U.K.). This sequence contains the seven amino acid residues predicted from the DNA sequence to be at the carboxy terminus of the 39K gene product (Davison, 1983) , linked to an amino terminal tyrosine residue to facilitate coupling of the peptide to BSA. The seven residue sequence is not present elsewhere in the 39K or in the 70K gene products. Antibody that immune-precipitated a VZV-induced protein was detected 4 weeks after the third boosting immunization. The antibody reacted only weakly, presumably owing to its presence in the serum at a low concentration or to its low activity. Antigens were prepared from monolayers of human foetal lung cells which had been infected with the strain of VZV described by Dumas et al. (198l) and, when 50~ c.p.e, was observed, were labelled in methionine-free medium for 24 h at 37°C with 0.1 mCi/ml L- Fig. 1 were immune-precipitated with preimmune serum (lanes 1), peptide-induced antiserum (lanes 2), peptide-induced antiserum in the presence of free peptide at 2 pg/ml (lanes 3), 20 lag/ml (lanes 4) or 200 gg/ml (lanes 5), a monoclonal antibody againsi gC (lanes 6), a monoclonal antibody against gB (lanes 7) or anti-VZV human convalescent serum (lanes 8).
precleared using preimmune rabbit serum. In addition to those with rabbit antisera, immune precipitations were carried out using an anti-VZV human convalescent serum and two monoclonal antibodies reacting with VZV glycoproteins: antibody 5C3 reacting with gB, and antibody 2B6 reacting with gC (C. M. Edson & D. J. Waters, unpublished results). Immune complexes were prepared as described by Preston et aL (1984) using Staphylococcus aureus bacteria and analysed by electrophoresis in 10~ or 12~ (w/v) denaturing polyacrylamide gels [39:1 (w/w) acrylamide :N,N'-methylenebisacrylamide]. The gels were fixed, treated with En3Hance (New England Nuclear), dried and exposed to Kodak XS1 film for up to 4 months at -70 °C. Approximate molecular weights were calibrated using the published sizes of proteins (115K, 62K and 57K) reacting with monoclonal antibodies against gB (Keller et al., 1984) .
The fluorograph in Fig. 1 shows that the peptide-induced antiserum specifically precipitated [3H]mannose-labetled proteins with apparent molecular weights of 55K and 45K (gp55 and gp45) from VZV-infected cell antigens. Inspection of the original fluorograph suggested that small amounts of higher molecular weight glycoproteins (70K to 100K) were also precipitated. The two predominant glycoproteins were clearly different in mobility from those precipitated by the monoclonal antibody against gB. Proteins with molecular weights of 55K, 85K and 95K were detected in [3SS]methionine-labelled VZV antigens, although the diffuse bands were somewhat obscured by non-specifically precipitated proteins. It is unlikely that the two [35S]methionine-labelled proteins of 30K and 35K were unglycosylated precursors, since their precipitation was not inhibited by including free peptide in the reaction (data not shown). In contrast, the fluorograph in Fig. 2 shows that inclusion of free peptide completely inhibited Fig. 2 were precleared three times using a monoclonal antibody against (a) gC or (b) gB and aliquots were immune-precipitated with preimmune serum (lanes 1), peptide-induced antiserum (lanes 2), peptide-induced antiserum in the presence of 200 ~tg/ml free peptide (lanes 3), a monoclonal antibody against gC (lanes 4), a monoclonal antibody against gB (lanes 5) or anti-VZV human convalescent serum (lanes 6).
precipitation of gp55 from [3H]mannose-labelled VZV antigens. A different antigen preparation from that in Fig. 1 was used in Fig. 2 and 3 , and the amount of gp45 precipitated was barely detectable. Hence, it was difficult to establish whether precipitation of gp45 was also inhibited by free peptide in Fig. 2 , although partial inhibition was observed in Fig. 3 as described below. Therefore, it may be concluded from these results that the 39K gene encodes gp55 and perhaps gp45. The caveat, applicable to the results of all immune precipitation experiments, should be added that the results do not formally rule out the unlikely possibility that either or both of gp55 and gp45 are not the product of this gene, but were merely bound in the immune precipitation to the true product, which may be either gp55 or gp45 or a protein which was not detected. The products of the 39K gene were compared with previously identified VZV glycoproteins by experimental use of two available monoclonal antibodies and by considering the published reactivities of other monoclonal antibodies. Monoclonal antibodies against the three major antigenically distinct VZV glycoproteins have been reported by several groups (Grose et al., 1983 (Grose et al., , 1984 Okuno et al., 1983 ; Forghani et al., 1984; Keller et al., 1984; Vafai et al., 1984) , and Keller et al. (1984) have defined these as gA, gB and gC. gA has a molecular weight of 105K (Keller et al., 1984) , and therefore is unlikely to be related to gp55 and gp45. The mobilities of gp55 and gp45 may be compared in Fig. 2 with those of the antigens recognized by monoclonal antibodies against gB and gC. gp55 and gp45 were not at all similar in mobility to the glycoproteins recognized by the former, but they did co-migrate with species recognized by the latter. One possible interpretation of this observation is that gp55 and gp45 are related to gC but not to gB. To investigate this, antigens were preabsorbed with either of the two monoclonal antibodies before immune precipitation. The fluorograph in Fig. 3 , for which the same antigen preparation was used as in Fig. 2 , Shows that preabsorption removed nearly all of the appropriate glycoprotein species, but did not significantly inhibit precipitation ofgp55 and gp45 by the peptide-induced antiserum. Again, precipitation of gp55 was completely inhibited by free peptide, and, as mentioned above, partial inhibition of the precipitation of gp45 was detected, especially when the antigens had been preabsorbed with the monoclonal antibody against gB. The results of these experiments confirm that gp55 and gp45 are not related to gC or gB, and show that the species of gC which co-migrated with gp55 and gp45 are not related to these proteins. This conclusion is in accord with the observation that, even after absorption with the monoclonal antibody against gC, anti-VZV human convalescent serum precipitated appreciable amounts of proteins which co-migrated with gp55 and gp45. The lack of relationship between gC and gp55/gp45 is not surprising because gC is coded by the 70K gene (Ellis et al., 1985) , whereas gp55/gp45 are coded by the adjacent 39K gene. Okuno et al. (1983) reported three groups (2A, 2B, 2C) of monoclonal antibodies against VZV glycoproteins. Group 2A reacted with 94K and 83K glycoproteins, group 2B with 55K and 45K glycoproteins and very weakly with 94K and 83K glycoproteins, and group 2C with gB. The 45K glycoprotein was absent from virions, and was shown to be derived from the 55K glycoprotein and secreted into the infected cell medium. It is possible that groups 2A and 2B recognize products from a single glycoprotein gene, but the observation of Okuno et al. (1983) that the proteins recognized by 2B were synthesized via a 49K precursor strongly suggests that they represent a fourth family of glycoproteins distinct from those recognized by group 2A, which were synthesized via a 75K precursor and probably represent gC. There was no evidence that the two proteins of higher molecular weight recognized by group 2A and group 2B antibodies are identical. The similarity of the gel electrophoresis profile of proteins precipitated by group 2B antibodies to those precipitated by the peptide-induced antiserum suggests that group 2B antibodies may recognize the products of the 39K gene. This correlation is made rather tentatively, since it is based on similarities observed by indirect comparison of results from different laboratories, and must await direct confirmation. It should also be noted that a monoclonal antibody and a peptide-induced antiserum directed against the same glycoprotein family need not necessarily be expected to show identical immune precipitation profiles because they are likely to react with different epitopes. Nevertheless, if both group 2B antibodies and the peptide-induced antiserum indeed recognize the 39K gene products, this would indicate that the 55K and the 45K glycoproteins contain the carboxy terminus of the primary translation product.
The functions of gp55 and gp45 are unknown, but are probably shared by herpes simplex virus type 1 (HSV-1) since the 39K gene has a partially homologous counterpart in the Us component of the HSV-1 genome (McGeoch et al., 1985; A. J. Davison & D. J. McGeoch, unpublished results) . The mature protein coded by the HSV-1 counterpart to the 39K gene has not yet been identified, but the primary translation product has a predicted molecular weight of 41K. A counterpart to the VZV 70K gene is also contained in HSV-1 Us, and specifies gE, a glycoprotein which is able to bind to the Fc site of immunoglobulin molecules. HSV-1 Us contains three other potential glycoprotein genes for which no counterparts have been identified in VZV Us. The expectation that most, if not all, VZV glycoprotein genes have homologues in HSV-1 would facilitate the eventual unification of the presently evolving nomenclatures for VZV and HSV-1 glycoproteins.
The available data indicate at present that VZV expresses at least four separately encoded families of glycoproteins : gA, gB, gC and gp55/gp45. Two of these, gC and gp55/gp45, have been mapped to adjacent genes in the Us component of the VZV genome. The presence of at least three glycoprotein genes elsewhere in the genome is anticipated from an analysis of the complete VZV DNA sequence (A. J. Davison, unpublished results), and thus it is likely that a fifth family of glycoproteins remains to be identified. It is clear that peptide-induced antisera could be used to identify the products of the unmapped, and any as yet unsuspected, VZV glycoprotein genes.
